Clinical Trials Logo

Nausea clinical trials

View clinical trials related to Nausea.

Filter by:

NCT ID: NCT04747691 Completed - Clinical trials for Postoperative Complications

Assessing Gastric Motility and Distention in Postoperative Gastrointestinal Surgery Using Bedside Gastric Ultrasound: Predicting Risk of Aspiration Pneumonia, Ileus, Return of Bowel Function

Start date: February 12, 2021
Phase:
Study type: Observational [Patient Registry]

Point-of-care gastric ultrasound will be used to measure stomach contents postoperative in patients who underwent colorectal surgery. Stomach volume and status (empty or full) will be compared retrospectively to the standard clinical criteria for diet advancement to determine if stomach volume via ultrasound is associated with successful diet advancement, nausea/vomiting, nasogastric tube replacement, length of stay, and other clinical outcomes. Clinicians performing clinical care will be blinded to the ultrasound exam results.

NCT ID: NCT04742660 Completed - Clinical trials for Postoperative Nausea

The Effect of Glycyrrhizin on the Occurrence of Postoperative Nausea and Vomiting

Start date: May 11, 2021
Phase: N/A
Study type: Interventional

The investigators investigate the association between the administration of glycyrrhizin during induction of general anesthesia and the occurrence of postoperative nausea and vomiting (PONV) in patients undergo breast surgery

NCT ID: NCT04726436 Completed - Clinical trials for Postoperative Nausea and Vomiting

Dextrose Effect on Postoperative Nausea and Vomiting (PONV)

Start date: January 25, 2021
Phase: N/A
Study type: Interventional

The aim of this study to assess which time and dose of dextrose solution more effective in decreasing postoperative nausea and vomiting.

NCT ID: NCT04719910 Completed - Clinical trials for Postoperative Nausea and Vomiting

Food Related Video and the Incidence of Postoperative Nausea and Vomiting

Start date: September 1, 2021
Phase: N/A
Study type: Interventional

Postoperative nausea/vomiting (PONV) is a common problem following surgery and anesthesia. There are risk factors that increase the incidence of PONV that are related to the patient, to the surgical procedure or to the anesthetic agents. At the subjective level PONV is described as worse and more feared than postoperative pain by many patients. At the objective level it increases the length of stay in the recovery room, it results in unplanned hospital admission and Emergency Room visits, and therefore increased cost of care. A lot of research work has been done to identify pharmacological agents to prevent and treat PONV. The higher the risk of a patient the higher number of these drugs are combined for prophylaxis. However, these drugs have significant side effects of their own. Much less attention has been paid to potential non-pharmacological PONV prevention options. The purpose of our study is to investigate the putative role of the natural stimulation of normal gastrointestinal function via the Pavlovian reflex. We seek to find a natural method with no side effects to improve PONV prophylaxis in patients with risk factors for that postoperative complication.

NCT ID: NCT04718727 Completed - Clinical trials for Postoperative Nausea

Olanzapine for the Prevention of Postoperative Nausea and Vomiting

Start date: March 15, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

Nausea and vomiting (PONV) remain a common problem in surgical units. Even after two or three prophylactic antiemetic interventions, patients with all four of the Apfel risk factors for PONV have an estimated 30 to 40% chance of suffering PONV. Olanzapine as an antiemetic represents a new use of an antipsychotic drug.

NCT ID: NCT04715932 Completed - Pain Clinical Trials

Study of Hesperidin Therapy on COVID-19 Symptoms (HESPERIDIN)

Hesperidin
Start date: February 18, 2021
Phase: Phase 2
Study type: Interventional

The main aim of this study is to determine the effects of short-term treatment with hesperidin on COVID-19 symptoms in comparison with a placebo. Treatment effects will be observed through a symptoms diary that will be completed by participants throughout the study and by taking the oral temperature daily.

NCT ID: NCT04693832 Completed - Oncology Clinical Trials

The Effect of Using Interactive Mobile Application for the Management of Chemotherapy- Induced Nausea and Vomiting in Children

Start date: January 1, 2019
Phase: N/A
Study type: Interventional

The aim of this study was to develop an interactive mobile application and to investigate the effect of this application on the management of nausea and vomiting symptoms by using it during chemotherapy treatment.

NCT ID: NCT04669132 Completed - Clinical trials for Nausea Post Chemotherapy

Efficacy of Olanzapine, Netupitant and Palonosetron in Controlling Nausea and Vomiting Associated With Highly Emetogenic Chemotherapy in Patients With Breast Cancer

OLNEPA
Start date: December 17, 2020
Phase: Phase 2
Study type: Interventional

This is a longitudinal, one arm, prospective phase II study, designed to evaluate the efficacy of Olanzapine Netupitant and Palonosetron in the controll of nausea and vomiting induced by highly emetogenic chemotherapy.

NCT ID: NCT04651608 Completed - Pediatric Cancer Clinical Trials

The Effect of Acupressure Chemotherapy-related Nausea Vomiting in Children

Start date: March 1, 2017
Phase: N/A
Study type: Interventional

This study is carried out to evaluate and compare the efficiency of acupressure practice applied with pressure or sea-band and their placebo on managing the acute nausea-vomiting symptoms developing due to chemotherapy in pediatric oncology patients.

NCT ID: NCT04622618 Completed - Pain, Postoperative Clinical Trials

Optimal Dosing of Preoperative Gabapentin for Prevention of Postoperative Nausea and Vomiting

Start date: September 15, 2020
Phase: Early Phase 1
Study type: Interventional

Overall incidence of postoperative nausea and vomiting (PONV) after general anesthesia is 40-90 % . gabapentin has been incorporated into "fast-track" packages and improved recovery during surgery protocols to avoid unintended side effects associated with opioid alternatives. Interestingly, gabapentin has also been noted to reduce the effects of chemotherapy-induced nausea, effective in treatment of gravidarum hyperemesis, and postdural puncture emesis. Different dosing regimens were tested.The goal of the study is to determine the most effective dose of oral gabapentin given 1 hour prior to surgery on the occurrence and severity of PONV and drug side effects in the first 24 hours postoperatively to find the most effective dose of gabapentin with the least side effects.